BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Prognosis
113 results:

  • 1. High expression of BCat1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response.
    Pan J; Wang Y; Huang S; Mao S; Ling Q; Li C; Li F; Yu M; Huang X; Huang J; Lv Y; Li X; Ye W; Wang H; Wang J; Jin J
    J Mol Med (Berl); 2024 Mar; 102(3):415-433. PubMed ID: 38340163
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [Clinical and molecular biological characterization of patients with accelerated chronic lymphocytic leukemia].
    Zhou ZY; Dai LMJ; Sha YQ; Qiu TL; Qin SC; Miao Y; Xia Y; Wu W; Tang HN; Xu W; Li JY; Zhu HY
    Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):917-923. PubMed ID: 38185521
    [No Abstract]    [Full Text] [Related]  

  • 3. Chronic Lymphocytic leukemia IGHV Somatic Hypermutation Detection by Targeted Capture Next-Generation Sequencing.
    Grants JM; May C; Bridgers J; Huang S; Gillis S; Meissner B; Boyle M; Ben-Neriah S; Hung S; Duns G; Hilton L; Gerrie AS; Marra M; Kridel R; Sabatini PJB; Steidl C; Scott DW; Karsan A
    Clin Chem; 2024 Jan; 70(1):273-284. PubMed ID: 38175592
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. DNA Copy Number Alterations and Copy Neutral Loss of Heterozygosity in Adult Ph-Negative Acute B-Lymphoblastic leukemia: Focus on the Genes Involved.
    Risinskaya N; Gladysheva M; Abdulpatakhov A; Chabaeva Y; Surimova V; Aleshina O; Yushkova A; Dubova O; Kapranov N; Galtseva I; Kulikov S; Obukhova T; Sudarikov A; Parovichnikova E
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139431
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naïve CLL patients.
    Navrkalova V; Plevova K; Radova L; Porc J; Pal K; Malcikova J; Pavlova S; Doubek M; Panovska A; Kotaskova J; Pospisilova S
    Br J Haematol; 2024 Jan; 204(1):240-249. PubMed ID: 38062779
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Long-Smoldering T-prolymphocytic leukemia: A Case Report and a Review of the Literature.
    Gjelberg HK; Helgeland L; Liseth K; Micci F; Sandnes M; Russnes HG; Reikvam H
    Curr Oncol; 2023 Nov; 30(11):10007-10018. PubMed ID: 37999147
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Clinical characteristics, treatment options, and prognosis of myeloid sarcoma: analysis using the SEER database.
    Liang J; Yang L; Yang B; Tian Y; Ren J; Yang L
    Hematology; 2023 Dec; 28(1):2247898. PubMed ID: 37594298
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Molecular characteristics in Chinese with chronic lymphocytic leukemia by next-generation sequencing: A single-center retrospective analysis.
    Cao Y; Chen Y; Tao T; Gong Y; Xu C; Cen J; Shen H; Pan J; Chen S; Yao L
    Int J Lab Hematol; 2023 Dec; 45(6):908-916. PubMed ID: 37551448
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. MYH9 Facilitates Cell Invasion and Radioresistance in Head and Neck Cancer via Modulation of Cellular ROS Levels by Activating the MAPK-Nrf2-GCLC Pathway.
    You GR; Chang JT; Li YL; Huang CW; Tsai YL; Fan KH; Kang CJ; Huang SF; Chang PH; Cheng AJ
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139430
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia.
    Mikhaylenko N; Wahnschaffe L; Herling M; Roeder I; Seifert M
    PLoS One; 2022; 17(9):e0274463. PubMed ID: 36129940
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Dynamics of minimal residual disease defines a novel risk-classification and the role of allo-HSCT in adult Ph-negative B-cell acute lymphoblastic leukemia.
    Cai Z; Liu Y; Tang B; Wu Z; Wang Z; Lin R; Xu X; Huang Z; Ou J; Li X; Liu X; Liu Q; Zhou H
    Leuk Lymphoma; 2022 Dec; 63(13):3181-3190. PubMed ID: 36098226
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Methylation of DNA Repair Genes as a Prognostic Biomarker in AML of a TCGA-LAML Cohort.
    Park S; So MK; Huh J
    Clin Lab; 2022 Jul; 68(7):. PubMed ID: 35975527
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features.
    Pérez-Carretero C; Hernández-Sánchez M; González T; Quijada-Álamo M; Martín-Izquierdo M; Santos-Mínguez S; Miguel-García C; Vidal MJ; García-De-Coca A; Galende J; Pardal E; Aguilar C; Vargas-Pabón M; Dávila J; Gascón-Y-Marín I; Hernández-Rivas JÁ; Benito R; Hernández-Rivas JM; Rodríguez-Vicente AE
    Am J Hematol; 2022 Jul; 97(7):903-914. PubMed ID: 35472012
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia.
    Jelloul FZ; Yang R; Garces S; Kanagal-Shamanna R; Ok CY; Loghavi S; Routbort MJ; Zuo Z; Yin CC; Floyd K; Bassett RL; Wierda W; Jain N; Thompson P; Luthra R; Medeiros LJ; Patel KP
    Leuk Res; 2022 May; 116():106827. PubMed ID: 35430388
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Does early disease progression predict survival after first line-treatment of Waldenström macroglobulinemia?
    Labreuche J; Assouan D; Durot E; Tomowiak C; Roos-Weil D; Toussaint E; Bijou F; Lemal R; Brion A; Laribi K; Ysebaert L; Duhamel A; Morel P;
    Hematol Oncol; 2022 Aug; 40(3):400-408. PubMed ID: 35385885
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Prognostic significance of atm mutations in chronic lymphocytic leukemia: A meta-analysis.
    Baghaei Vaji F; Boroumand Nasr A; Rezvani A; Ayatollahi H; Goudarzi S; Lavasani S; Bagheri R
    Leuk Res; 2021 Dec; 111():106729. PubMed ID: 34735935
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11.
    Lafage-Pochitaloff M; Gerby B; Baccini V; Largeaud L; Fregona V; Prade N; Juvin PY; Jamrog L; Bories P; Hébrard S; Lagarde S; Mansat-De Mas V; Dovey OM; Yusa K; Vassiliou GS; Jansen JH; Tekath T; Rombaut D; Ameye G; Barin C; Bidet A; Boudjarane J; Collonge-Rame MA; Gervais C; Ittel A; Lefebvre C; Luquet I; Michaux L; Nadal N; Poirel HA; Radford-Weiss I; Ribourtout B; Richebourg S; Struski S; Terré C; Tigaud I; Penther D; Eclache V; Fontenay M; Broccardo C; Delabesse E
    Blood Adv; 2022 Jan; 6(2):386-398. PubMed ID: 34638130
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia.
    Quijada-Álamo M; Pérez-Carretero C; Hernández-Sánchez M; Rodríguez-Vicente AE; Herrero AB; Hernández-Sánchez JM; Martín-Izquierdo M; Santos-Mínguez S; Del Rey M; González T; Rubio-Martínez A; García de Coca A; Dávila-Valls J; Hernández-Rivas JÁ; Parker H; Strefford JC; Benito R; Ordóñez JL; Hernández-Rivas JM
    Clin Transl Med; 2021 Feb; 11(2):e304. PubMed ID: 33634999
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A reduced panel of eight genes (atm, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia.
    Chauzeix J; Pastoret C; Donaty L; Gachard N; Fest T; Feuillard J; Rizzo D
    Int J Lab Hematol; 2021 Aug; 43(4):683-692. PubMed ID: 33325634
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.
    Seok JY; Astvatsaturyan K; Peralta-Venturina M; Lai J; Fan X
    Int J Surg Pathol; 2021 Jun; 29(4):368-377. PubMed ID: 33289434
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 6.